Disease progression in cancer treatments can be complex, especially when it comes to commonly used medications like Lorlatinib or Osimertinib. Dive deep into this crucial topic with Dr. Millie Das and Angel Qin in the 2022 Targeted Therapies Forum. Unravel the intricacies of how these medications work, why there might be progression, and what steps can be taken next.
We are deeply thankful to our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their commitment to fostering patient education and advocacy.
To further your knowledge on the evolving landscape of cancer treatments and therapies, head over to http://cancerGRACE.org/. Engage with a community of experts, patients, and caregivers by joining the discussion at https://cancergrace.org/forum.